Clinical trials group Hvivo announces departure from Irish stock market

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 36 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 98%

Hvivo 뉴스

Cathal-Friel,Euronext

Company says its primary operations, along with the majority of its employees and investor base, are based in the UK

Listed clinical trials group Hvivo has announced it will remove its shares from the Irish market later this year.

Hvivo was formed when the group’s chairman Cathal Friel reversed his pharma services business of the same name into Dublin-listed drug clinical trials manager Venn Life Sciences.Nursing home fees: can I claim tax relief on behalf of my dad? The cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on Hvivo’s ordinary shares which will continue to trade on AIM under the ticker “HVO”.

Mr Friel sold his remaining shares in the group last month “to satisfy institutional demand” after that capital markets day, the company said, raising £6.14 million for the 3.1 per cent stake at 29 pence each.

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 3. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인